{
  "abstract": "Background: Real-world data for intranasal esketamine in treatment-resistant depression (TRD) are needed to characterize effectiveness, suicidality, and tolerability in routine care. We evaluated induction phase outcomes in outpatients with TRD treated at the University Hospital Vienna.\n\nMethods: This retrospective single-center registry study included adults with TRD initiating supervised intranasal esketamine. The primary endpoint was the change in clinician-rated depressive symptom severity (MADRS) from the pre-treatment (PV) to the end of induction (EOI) visit. MADRS scores across baseline (BL), PV, and EOI were analyzed using a mixed model for repeated measures. Secondary outcomes included MADRS three-factor change, self-rated depression score trajectories (PHQ-9), response/remission rates, suicidal ideation, and tolerability.\n\nResults: Of 229 screened patients, 176 initiated esketamine and 156 completed induction. MADRS at BL was 31.5 (SD 6.4), PHQ-9 was 18.5 (SD 4.7). In the primary model, adjusted mean MADRS was 30.3 at PV and 17.7 at EOI, yielding a change of −12.5 points (95%CI −14.1 to −11.0; p < 0.001; Hedges’ g = 1.8). All MADRS factors improved, with the largest reduction in the affective–anhedonic domain. PHQ-9 decreased steadily across treatments. Remission was 27.2% and response 57.4% at EOI. Suicidal ideation decreased significantly; no suicide or serious self-harm occurred during induction. Adverse events (AEs) were recorded in 34.7%, with AE-related discontinuation in 3.4%.\n\nConclusions: Esketamine induction was associated with marked improvement in depressive symptoms and suicidality, with acceptable tolerability under supervised administration. Longer-term registry follow-up and controlled comparative studies are needed to further define the benefit–risk profile beyond induction phase.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna, Vienna, Austria",
    "Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Maximilian Preiss",
      "orcid": "0009-0000-5044-9090"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Valentin Popper",
      "orcid": "0000-0003-1134-3554"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Luna Helene Charlotte Faber",
      "orcid": "0009-0006-5185-0701"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Theresa Baumgartner",
      "orcid": "0009-0001-8186-3320"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Philip Miguel Baberis-Martinez",
      "orcid": "0009-0004-5841-9661"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Edda Winkler-Pjrek",
      "orcid": "0000-0002-5148-8566"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Gregor Gryglewski",
      "orcid": "0000-0002-7344-8071"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Lucie Bartova",
      "orcid": "0000-0002-1769-8025"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Siegfried Kasper",
      "orcid": "0000-0001-8278-191X"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Dan Rujescu-Balcu",
      "orcid": "0000-0002-1432-313X"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Lukas Pezawas",
      "orcid": "0000-0002-1329-6352"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/35bz865zzb16c.bib",
  "cited_by": 0,
  "doi": "10.1192/j.eurpsy.2026.12234",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13735771/",
  "id": "35bz865zzb16c",
  "issns": [
    "0924-9338",
    "1778-3585"
  ],
  "landing_url": "https://doi.org/10.1192/j.eurpsy.2026.12234",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2736|Treatment of Major Depression"
    ]
  ],
  "openalex": "W7165683706",
  "pdf_url": "https://www.cambridge.org/core/services/aop-cambridge-core/content/view/633BE9A5241649BE6AB2D1A03E262137/S0924933826122342a.pdf/div-class-title-real-world-effectiveness-and-safety-of-intranasal-esketamine-for-treatment-resistant-depression-data-from-the-entrd-registry-div.pdf",
  "pmcid": "PMC13735771",
  "pmid": "42333767",
  "published": "2026-06-23",
  "publisher": "Cambridge University Press",
  "ris": "https://research.draconitic.com/paper/35bz865zzb16c.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T12:21:23Z",
      "native_id": "PMC13735771",
      "source": "pmc",
      "url": "https://doi.org/10.1192/j.eurpsy.2026.12234"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2736|Treatment of Major Depression",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: Data from the enTRD registry",
  "title_text": "Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: Data from the enTRD registry",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T12:21:23Z",
  "url": "https://research.draconitic.com/paper/35bz865zzb16c",
  "venue": "European Psychiatry",
  "versions": []
}